

EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____
I hereby certify that, on the date indicated above, this paper
or fee was deposited with the U.S. Postal Service & that it
was addressed for delivery to the Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail
Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.: 07278

Docket No.: 02650/100F918US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kendall A. SMITH

Serial No.: 09/708,635

Confirmation No.: 2206

Filed: September 22, 2000

Group Art Unit: 1648

For: LOW DOSE IL-2 FOR POTENTIATION OF IMMUNITY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.56(a), attached hereto is a copy of
Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested
that each document cited (including any cited in applicant's specification which is
not repeated on the attached Form PTO-1449) be given thorough consideration
and that it be cited of record in the prosecution history of the present application

M:\2650\1f918\00063738.WPD [*26501F918*]

10/10/2003 MDAMTE1 00000018 09708635

01 FC:1806

180.00 OP

by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


Since some of the documents were known to the applicant for more than three months before the filing of this Information Disclosure Statement, the statutory fee of \$180.00 under 37 C.F.R. 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fees required in connection with this Petition or to credit any overpayment to Deposit Account No. 04-0100.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: October 2, 2003



Jason C. Chumney.
Registration No. 54,781
Agent for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/708,635
				Filing Date	September 22, 2000
				First Named Inventor	Kendall A. Smith
				Art Unit	1648
				Examiner Name	J. Parkin
Sheet	1	of	1	Attorney Docket Number	02650/100F918-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	6,509,313 B1	01/21/03	Smith	Entire Document
	AB	4,933,433	06/12/90	Tamblyn	Entire Document
	AC	4,938,956	07/03/90	Howard	Entire Document
	AD	5,420,109	05/30/95	Suto	Entire Document
	AE	4,940,456	07/10/90	Sibalis	Entire Document
	AF	5,126,129	06/30/92	Wiltout	Entire Document

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 97/41831	11/13/97	Cornell Research Foundation	Entire Document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	CALIGIURI, Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2, Journal of Clinical Investigation, 1993, p. 123-132	
	CB	TEPLER, Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection, Journal of Infectious Diseases, 1993; 167:291-298	
	CC	ANDERSON, Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2, Clinical Pharmacokinetics, 1994, 27; 1:19-31	
	CD	YAMAMOTO, Hepatic Arterial Infusion of Interleukin-2 in Advanced Hepatocellular Carcinoma, Acta Oncologica, 1993, 32; 1:43-51	
	CE	JACOBSON, Rational Interleukin 2 Therapy for HIV Positive Individuals: Daily Low Doses Enhance Immune Function Without Toxicity, Proceedings of the National Academy of Sciences of the United States of America, 1996, 93:10405-10410	
	CF	MEUER, Low Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg In Immunodeficient Non-Responders to Hepatitis B Vaccination, The Lancet, 1989, No. 8628, pp. 15-18.	
	CG	BERNSTEIN, Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity, Blood, 1995, 86; 9:3287-3294	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--